抄録
In a co-operative study on leukemia conducted at 17 National Hospitals during the 6 year period from July 1, 1959 through June 30, 1965, the prognosis of 151 cases of acute myeloblastic leukemia was examined with regard to presence or absence of the selected clinical manifestations such as fever, hemorrhage, level of white blood cell counts, percentage of myeioblast in peripheral blood and that of bone marrow at the initial examination on admission.
The rate of 8th week survival from the start of treatment was used as the prognostic index.
Of the 151 cases, 112 cases, were treated with corticosteroid and 6-Mercaptopurine in combination, 15 cases were treated with corticosteroid alone, and 14 cases were treated with a combination of corticosteroid, 6-Mercaptopurine and Nlitomycin-C.
1. The survival rate of the higher body temperature group (above 38°C) was 34.0% and that of the lower body temperature group (belew 38°C) was 46.9%; no statistically significant difference between these.
2. The survival rate of hemorrhagic group (29.6%) was lower than that of non-hemorrhagic group (53.7%) with statistical significance.
3. The survival rate of the group of higher level of white blood cell counts (above 50, 000/cmm) was 30.3% and that of the lower level group (below 50, 000/cmm) was 46.% no statistically significant difference between these.
4. The survival rate of the group of higher percentage of myeioblast in peripheral blood (above 80%) was 31.6% and that of the lower level group (below 80%) was 45.9%; no statistically significant difference between these.
5. The survival rate of the group of higher percentage of myeioblast in bone marrow (above 80%) was 43.7% and that of the lower level group (below 80%) was 41.7%; no statistically significant difference between these.
6. The survival rate of the cases with a lower level of body temperature in non-hemorrhagic group was 63.3%, that of the cases with a lower level of body temperature in hemorrhagic group was 35.1%, that of the cases with a higher level of body temperature in non-hemorrhagic group was 41.6% and that of the cases with a higher level of body temperature in hemorrhagic group was 29.1%; there were statistically significant differences between the first group and the second group and between the first group and the third group.
7. The survival rate of the cases of a lower percentage of myeloblast in peripheral blood in non-hemorrhagic group was 57.2%, that of the cases with a higher percentage of myeloblast in peripheral blood in non-hemorrhagic group was 50.0%, that of the cases with a lower percentage of myeloblast in peripheral blood in hemorrhagic group was 34.1% and that of the cases with a higher percentage of myeloblast in peripheral blood in hemorrhagic group was 21.7%; there were staististicalIy significant difference between the first group and the third group and between the first group and the fourth group.
8. The survival rate of the cases with a lower level of body temperature and a lower percentage of myeloblast in peripheral blood in hemorrhagic group was 48.2%, that of the cases with a lower level of body temperature and a higher percentage of myeloblast in peripheral blood in hemorrhagic group was 11.1%, that of the cases with a higher level of body temperature and a lower percentage of myeloblast in peripheral blood in hemorrhagic group was 36.3%, that of the cases with a higher level of body temperature and a higher percentage of myeloblast in peripheral blood in hemorrhagic group was 11.1%, that of the cases with a lower level of body temperature and a lower percentage of myeloblast in peripheral blood in non-hemorrhagic group was 68.3%, that of the cases with a lower level of body temperature and a higher percentage of myeloblast in peripheral blood in non-hemorrhagic group was 55.4%,
